Safety and Efficacy of Bevacizumab with Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

PURPOSE: Preclinical studies suggest that inhibition of vascular endothelial growth factor (VEGF) improves glioma response to radiotherapy. Bevacizumab, a monoclonal antibody against VEGF, has shown promise in recurrent gliomas, but the safety and efficacy of the concurrent use of bevacizumab with b...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gutin, Philip H., Iwamoto, Fabio M., Beal, Kathryn, Mohile, Nimish A., Karimi, Sasan, Hou, Bob L., Lymberis, Stella, Yamada, Yoshiya, Chang, Jenghwa, Abrey, Lauren E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3659401/
https://ncbi.nlm.nih.gov/pubmed/19167838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijrobp.2008.10.043
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky